DR. CALVIN KUO, M.D. PH.D.
Osteopathic Medicine at Campus Dr, Palo Alto, CA
License number
California G86636
Category
Osteopathic Medicine
Type
Hematology
Address
Address
269 Campus Dr, Palo Alto, CA 94305
Phone
(650) 736-1428
Organization information
See more information about CALVIN KUO at bizstanding.comCalvin Kuo MD,PHD
269 Campus Dr, Stanford, CA 94305
Industry:
Internist
Phone:
(650) 736-1428 (Phone)
Calvin Jay Kuo
Professional information
Dr. Calvin Kuo, Stanford CA - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
STANFORD COMPREHENSIVE CANCER CENTER AT STANFORD UNIVERSITY MEDICAL CENTER
269 Campus Dr, Stanford 94305
(650) 725-5447 (Phone), (650) 725-1420 (Fax)
269 Campus Dr, Stanford 94305
(650) 725-5447 (Phone), (650) 725-1420 (Fax)
Certifications:
Internal Medicine, 1997, Medical Oncology, 2001
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
STANFORD COMPREHENSIVE CANCER CENTER AT STANFORD UNIVERSITY MEDICAL CENTER
269 Campus Dr, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
269 Campus Dr, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical School
Stanford University
Graduated: 1994
Stanford University
Graduated: 1994
Calvin Kuo, Stanford CA
Specialties:
Internist
Address:
300 Pasteur Dr, Stanford, CA 94305
269 Campus Dr, Stanford, CA 94305
269 Campus Dr, Stanford, CA 94305
Education:
Doctor of Medicine
Methods To Regulate Glucose Metabolism
US Patent:
2010033, Dec 30, 2010
Filed:
Jun 29, 2010
Appl. No.:
12/825602
Inventors:
Calvin J. Kuo - Palo Alto CA, US
Kevin Wei - Stanford CA, US
Kevin Wei - Stanford CA, US
International Classification:
A61K 39/395, A61K 31/7088, C07K 16/00, C07H 21/04, A61P 3/10, C12N 5/071
US Classification:
4241581, 4241301, 4241721, 514 44 R, 514 44 A, 5303871, 5303891, 5303892, 536 231, 536 245, 435375
Abstract:
The present disclosure describes an unexpected and novel insight into hepatic insulin resistance through the description of the ability of VEGF inhibitors to revert hyperglycemia and hyperinsulimenia in murine Type 2 diabetes mellitus models through modulation of a HIF-2α-IRS-2 axis operative in hepatocytes. As such, the data of the present disclosure uncover a novel pathway regulating hepatic IRS-2 expression, and identify VEGF inhibitors as an FDA-approved class of therapeutics capable of increasing liver IRS levels and ameliorating Type 2 diabetes mellitus. Accordingly, this disclosure identifies stabilization of HIF-2α as a robust method for improving glucose metabolism. The disclosure provides embodiments of a method of modulating the level of glucose metabolism of a mammalian cell, comprising: contacting a mammalian cell with an effective amount of a composition, where the composition can modulate the levels of HIF-2α and IRS-2 activity in said cell, thereby modulating the level of glucose metabolism by said cell. The disclosure also provides embodiments of a pharmaceutical composition and methods for their use for the treatment of Type 2 diabetes in an animal or human subject, the method comprising administering to an animal or human subject a effective amount of a pharmaceutically acceptable composition, the composition, when administered to an animal or human subject, increasing the activity of HIF-2α and IRS-2 in the animal or human subject, thereby reducing the level of blood glucose in the animal or human subject.
Ex Vivo Culture, Proliferation And Expansion Of Intestinal Epithelium
US Patent:
2010004, Feb 25, 2010
Filed:
Aug 21, 2009
Appl. No.:
12/545755
Inventors:
Calvin Jay Kuo - Palo Alto CA, US
Akifumi Ootani - Stanford CA, US
Akifumi Ootani - Stanford CA, US
International Classification:
C12Q 1/04, C12N 5/071, C12Q 1/02
US Classification:
435 34, 435325, 435 29
Abstract:
Methods are provided for long term culture of mammalian intestinal cells. Cultures are initiated with fragments of mammalian intestinal tissue, which are then maintained embedded in a gel substrate that provides an air-liquid interface. Intestinal epithelium in cultures of the invention can be continuously grown for extended periods of time. Mammalian intestinal cells cultured by the methods of the invention recapitulate features of intestinal growth in vivo.
Methods Of Modulating Angiogenesis
US Patent:
2010027, Nov 4, 2010
Filed:
May 23, 2008
Appl. No.:
12/600984
Inventors:
Frank Kuhnert - Palo Alto CA, US
Hsiao-Ting Wang - Redwood City CA, US
Calvin Jay Kuo - Palo Alto CA, US
Hsiao-Ting Wang - Redwood City CA, US
Calvin Jay Kuo - Palo Alto CA, US
International Classification:
A61K 39/395, A61K 31/711, A61K 31/7105, A61K 31/713, A61P 25/00, A61P 9/10, A61P 3/10, A61P 35/00
US Classification:
4241301, 514 44 A, 514 44 R
Abstract:
The present invention provides methods of modulating angiogenesis in an individual, the methods generally involving administering to an individual an agent that modulates the expression or activity of GPR124. In one embodiment, the methods of the invention relate to inhibiting pathological angiogenesis by decreasing activity of GPR124, which method may be carried out in conjunction with administration of one or more other anti-angiogenic agents.
Method For Treating Cancer And Increasing Hematocrit Levels
US Patent:
2006001, Jan 19, 2006
Filed:
Jun 15, 2005
Appl. No.:
11/153086
Inventors:
Calvin Kuo - Palo Alto CA, US
Richard Mulligan - Cambridge MA, US
Richard Mulligan - Cambridge MA, US
Assignee:
CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY - Palo Alto CA
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY - Palo Alto CA
International Classification:
A61K 38/17, A61K 48/00
US Classification:
514002000, 424093200
Abstract:
The present invention provides a method for inhibiting undesired angiogenesis including tumor-associated angiogenesis. The invention further provides a method for increasing the number of red blood cells or hematocrit in the circulation in subjects in need thereof. The invention also provides a method for simultaneously treating low hematocrit and undesired angiogenesis. Additionally, the present invention provides a method for determining efficacy or endpoint of treatment with one or more VEGF-inhibitors.
Modulation Of Gastrointestinal Epithelium Proliferation Through The Wnt Signaling Pathway
US Patent:
2005016, Aug 4, 2005
Filed:
Oct 4, 2004
Appl. No.:
10/958531
Inventors:
Calvin Kuo - Stanford CA, US
International Classification:
A61K009/64, A61K009/24, A61K038/17, A61K048/00
US Classification:
424472000, 514002000, 514044000
Abstract:
These results indicate the efficacy of systemic expression of secreted Wnt antagonists as a general strategy for conditional inactivation of Wnt signaling in adult organisms, and illustrate a striking reliance on a single growth factor pathway for the maintenance of the architecture of the adult small intestine and colon. These results also indicate the potential utility of administration of Wnt pathway agonists for mucosal repair of the small intestine or colon.
Method For Treating Cancer And Increasing Hematocrit Levels
US Patent:
2004013, Jul 8, 2004
Filed:
Feb 10, 2004
Appl. No.:
10/467509
Inventors:
Calvin Kuo - Palo Alto CA, US
Richard Mulligan - Cambridge MA, US
Richard Mulligan - Cambridge MA, US
International Classification:
A61K048/00
US Classification:
514/044000, 424/093200
Abstract:
The present invention provides a method for inhibiting undesired angiogenesis including tumor-associated angiogenesis. The invention further provides a method for increasing the number of red blood cells or hematocrit in the circulation in subjects in need thereof. The invention also provides a method for simultaneously treating low hematocrit and undesired angiogenesis. Additionally, the present inventio provides a method for determining efficacy or endpoint of treatment with one or more VEGF-inhibitors.
Methods Of Modulating Angiogenesis
US Patent:
7947278, May 24, 2011
Filed:
Jul 17, 2007
Appl. No.:
11/879655
Inventors:
Calvin Jay Kuo - Palo Alto CA, US
Frank Kuhnert - Palo Alto CA, US
Frank Kuhnert - Palo Alto CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 39/38, A61K 31/00, A61K 38/00, A01N 61/00, A01N 37/18
US Classification:
4241841, 514 1, 514 2
Abstract:
The present invention provides methods of modulating angiogenesis in an individual, the methods generally involving administering to an individual an agent that modulates the expression or activity of Egfl7, where an agonist of Egfl7, including an Egfl7 polypeptide, decreases angiogenesis. In one embodiment, the methods of the invention relate to inhibiting pathological angiogenesis by enhancing activity of Egfl7, which method may be carried out in conjunction with administration of one or more other anti-angiogenic agents.
Use Of Wnt Inhibitors To Augment Therapeutic Index Of Chemotherapy
US Patent:
7803783, Sep 28, 2010
Filed:
Feb 16, 2007
Appl. No.:
11/707386
Inventors:
Mark Lee - Los Altos Hills CA, US
Calvin Jay Kuo - Stanford CA, US
Tannishtha Reya - Chapel Hill NC, US
Irving L. Weissman - Stanford CA, US
Calvin Jay Kuo - Stanford CA, US
Tannishtha Reya - Chapel Hill NC, US
Irving L. Weissman - Stanford CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 31/713
US Classification:
514 44R, 435455, 435375, 514 12
Abstract:
Methods and compositions are provided for the protection of normal cells from cytoreductive therapy that target proliferating cells, by administering an inhibitor of Wnt signaling pathways. Wnt signaling is critically important for homeostasis of the epithelial lining of the adult intestine and other proliferating normal adult tissues.